Drug Trial Radar · NCT06309485
Phase 2 Study of WGI-0301 for Advanced HCC
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 31, 2024
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Zhejiang Haichang Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have previously received PD-1 / PD-L1 immune checkpoint inhibitors.
Conditions
- Advanced Hepatocellular Carcinoma (HCC)
Interventions
WGI-0301 at MTD/RP2D dose IV infusion, QWDrug
WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
WGI-0301 at MTD/RP2D -1 dose IV infusion, QWDrug
WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
Sorafenib 400 mg PO, BID continuouslyDrug
Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
Sorafenib 400 mg PO, BIDDrug
Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of WGI-0301 in combination with Sorafenib based on ORR per RECIST 1.1.Time frame: through study completion, an average of 2 year
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Hunan Cancer Hospital
Changsha, China · Recruiting
West China Hospital Sichuan University
Chengdu, China · Recruiting
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, China · Not yet recruiting
Tongji Hospital Tongji Medical College of HUST
Wuhan, China · Recruiting
China Pharmaceutical University, Shanghai Gobroad Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Prince of Wales Hospital
Hong Kong, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.